Artikel ; Online: Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk.
2023 Band 38, Heft 6, Seite(n) 515–520
Abstract: Purpose of review: Review the clinical outcomes of different antithrombotic strategies in patients with high bleeding risk (HBR) after percutaneous coronary intervention (PCI).: Recent findings: Patients with HBR after PCI include those with advanced ...
Abstract | Purpose of review: Review the clinical outcomes of different antithrombotic strategies in patients with high bleeding risk (HBR) after percutaneous coronary intervention (PCI). Recent findings: Patients with HBR after PCI include those with advanced age (e.g. >75 years of age), a prior history of major bleeding, anemia, chronic kidney disease, and those with indications for long-term anticoagulation. Strategies that successfully decrease bleeding risk in this population include shorter durations of dual antiplatelet therapy (DAPT; of 1-3 months) followed by single antiplatelet therapy with aspirin or a P2Y 12 inhibitor, or de-escalating from a more potent P2Y 12 inhibitor (prasugrel or ticagrelor) to less potent antiplatelet regimens (aspirin with clopidogrel or half-dose ticagrelor or half-dose prasugrel). Patients on DAPT, and a full dose anticoagulation for other indications, have a lower risk of major bleeding without an increase in 1-2-year adverse ischemic events, when rapidly switched from DAPT to a single antiplatelet therapy (within a week after PCI) with aspirin or clopidogrel. Longer term data on the benefits and risks of these strategies is lacking. Summary: In patients with HBR after PCI, shorter durations of DAPT (1-3 months) decrease the risk of major bleeding without increasing the risk of adverse ischemic events. |
---|---|
Mesh-Begriff(e) | Humans ; Platelet Aggregation Inhibitors ; Clopidogrel/therapeutic use ; Clopidogrel/adverse effects ; Ticagrelor/adverse effects ; Prasugrel Hydrochloride/therapeutic use ; Fibrinolytic Agents/adverse effects ; Percutaneous Coronary Intervention/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/prevention & control ; Aspirin ; Anticoagulants/adverse effects ; Treatment Outcome ; Acute Coronary Syndrome/drug therapy |
Chemische Substanzen | Platelet Aggregation Inhibitors ; Clopidogrel (A74586SNO7) ; Ticagrelor (GLH0314RVC) ; Prasugrel Hydrochloride (G89JQ59I13) ; Fibrinolytic Agents ; Aspirin (R16CO5Y76E) ; Anticoagulants |
Sprache | Englisch |
Erscheinungsdatum | 2023-07-28 |
Erscheinungsland | United States |
Dokumenttyp | Review ; Journal Article |
ZDB-ID | 645186-x |
ISSN | 1531-7080 ; 0268-4705 |
ISSN (online) | 1531-7080 |
ISSN | 0268-4705 |
DOI | 10.1097/HCO.0000000000001075 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 2556: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.